BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Cannabis and Sexual Health Survey
Genester Wilson-King, MD and Dr. Michael Eisenberg are conducting research on cannabis and sexual health at Stanford University. The survey will provide an opportunity for the general public to participate in cannabis research.
Short- and Long-Term Effects of Cannabis on Headache and Migraine.
Authors: Carrie Cuttler, Alexander Spradlin, Michael J. Cleveland, Rebecca M. Craft
The Journal of Pain, 9 November 2019
—
Use of cannabis to alleviate headache and migraine is relatively common, yet research on its effectiveness remains sparse. We sought to determine whether inhalation of cannabis decreases headache and migraine ratings as well as whether gender, type of cannabis (concentrate vs…
Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.
Authors: Vivek S. Kumawat, Ginpreet Kaur
European Journal of Pharmacology, 5 November 2019
—
The biological effects of endocannabinoid system are mediated by two types of receptors, cannabinoid 1 (CB1) and cannabinoid 2 receptor (CB2). They play a pivotal role in the management of pain, inflammation, cancer, obesity and diabetes mellitus. CB2 receptor activity downreg…
Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats.
Authors: Kelly A. Deabold,Wayne S. Schwark,Lisa Wolf and Joseph J. Wakshlag Published in Animals 19 October 2019 Abstract The use of CBD-rich hemp products is becoming popular among pet…
Novel interventions to reduce oxidative-stress related brain injury in neonatal asphyxia.
Authors: A.L. Solevåga, G.M. Schmölzer, P.-Y.Cheung
Free Radical Biology and Medicine, October 2019
—
Perinatal asphyxia-induced brain injury may present as hypoxic-ischemic encephalopathy in the neonatal period, and disability including cerebral palsy in the long term. The brain injury is secondary to both the hypoxic-ischemic event and the reoxygenation-reperfusion following…
Concomitant Treatment of Malignant Brain Tumours With CBD – A Case Series and Review of the Literature.
Authors: Rudolf Likar, Markus Koestenberger, Martin Stultschnig, Gerhard Nahler
Anticancer Research, October 2019
—
Grade IV glioblastoma multiforme is a deadly disease, with a median survival of around 14 to 16 months. Maximal resection followed by adjuvant radiochemotherapy has been the mainstay of treatment since many years, although survival is only extended by a few months. In recent y…
The effectiveness of self-directed medical cannabis treatment for pain.
Authors: Xiaoxue Li, Jacob M.Vigil, Sarah S. Stith, Franco Brockelman, Keenan Keeling, Branden Hall
Complementary Therapies in Medicine, October 2019
—
The prior medical literature offers little guidance as to how pain relief and side effect manifestation may vary across commonly used and commercially available cannabis product types. We used the largest dataset in the United States of real-time responses to and side effect r…
A History of the US Medical Cannabis Movement and Its Importance to Pediatricians
SCC member Kevin M. Takakuwa, MD outlines on the historical impact of cannabis and its relevance to pediatric practice. The article highlights how cannabis may benefit seizure disorders in children and young adults.
Cannabis and Pain.
Authors: Ethan B. Russo
Pain Medicine, 16 September 2019
—
This editorial is occasioned by the publication in Pain Medicine of two quite distinct articles [1,2] on the topical subject of cannabis and pain. As a point of departure, it is necessary to define terms. Cannabis sativa L. is a highly variable biochemical and morphological pl…
Immune Responses Regulated by Cannabidiol.
Authors: James M. Nichols and Barbara L.F. Kaplan
Cannabis and Cannabinoid Research, 4 September 2019
—
Introduction: Cannabidiol (CBD) as Epidiolex® (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabi…
Cannabinoid hyperemesis syndrome: a review of the literature.
Authors: Eleonore Deceuninck, Denis Jacques
Psychiatria Danubina, September 2019
—
BACKGROUND: Cannabinoid Hyperemesis Syndrome (CHS) is characterized by cyclic vomiting and compulsive need to take hot showers in the context of chronic cannabis use. Physicians’ lack of knowledge of CHS often results in a diagnostic delay of several years. The purpose of this…
Medical Use of Cannabis in 2019.
Authors: Kevin P. Hill
JAMA, 9 August 2019
—
Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the…